MediWound (NASDAQ:MDWD) Rating Increased to Sell at Wall Street Zen

MediWound (NASDAQ:MDWD) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Tuesday, April 21st. Oppenheimer restated an “outperform” rating and set a $32.00 price target (down from $33.00) on shares of MediWound in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of MediWound in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.00.

MediWound Stock Performance

MediWound stock opened at $14.33 on Friday. The company has a 50-day simple moving average of $16.62 and a 200-day simple moving average of $17.44. The firm has a market capitalization of $184.14 million, a P/E ratio of -6.34 and a beta of 0.21. MediWound has a one year low of $14.14 and a one year high of $22.50.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.42. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. As a group, sell-side analysts forecast that MediWound will post -2.75 earnings per share for the current year.

Institutional Investors Weigh In On MediWound

Institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in MediWound in the fourth quarter worth about $26,000. BNP Paribas Financial Markets lifted its holdings in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the 4th quarter valued at about $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.